在患有Fontan循环的患者中使用-葡萄糖共运输体-2 抑制剂
Stephanie S Gaydos1, Kimberly E McHugh1, Frances K Woodard1
1Division of Pediatric Cardiology, Department of Pediatrics, Medical University of South Carolina, Charleston, SC, USA.
Cardiology in the young
|February 26, 2025
概括
-葡萄糖共传输体-2 抑制剂在治疗Fontan循环患者的充血性心力衰竭中似乎是安全的. 这项研究发现了良好的耐受性,很少停止治疗,这表明这种独特人群的潜在益处.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 与双心室循环相比,Fontan循环中的充血性心力衰竭 (CHF) 带来了独特的挑战.
- -葡萄糖共运输体-2 (SGLT2) 抑制剂在降低心血管结局的有效性已被证明在CHF患者与双心室循环.
- 关于SGLT2抑制剂在Fontan循环患者中的使用和结果的数据有限.
研究的目的:
- 评估SGLT2抑制剂在被诊断为Fontan循环和CHF的患者中的安全性和耐受性.
- 评估SGLT2抑制剂对这一特定患者群体临床结果的影响.
主要方法:
- 一项单一中心的综述对Fontan循环的患者进行,这些患者被处方为CHF的SGLT2抑制剂.
- 测量的主要结果是药物的耐受性和停止治疗的必要性.
- 二次结局包括纽约心脏协会课程的变化,CHF住院,心室功能,运动能力和实验室标记.
主要成果:
- 确定了25名患有丰坦血流的患者 (大多数患有全身右心室).
- 超过三分之一的人患有基线中度至重度的腹腔功能障碍,59%的人表现出隐藏的腹腔功能障碍.
- 一般来说,SGLT2抑制剂的耐受性很好,仅有两次因感知到的副作用而停止使用;在二次结果中没有观察到显著变化,尽管趋势表明了潜在的益处.
结论:
- SGLT2 抑制剂在患有Fontan 循环的患者中证明了作为心血管衰竭治疗的安全性和耐受性.
- 这项研究代表了该人群中SGLT2抑制剂使用的最大发表系列.
- 建议进行进一步的研究,以充分了解SGLT2抑制剂在Fontan循环的独特背景下的治疗潜力.
相关概念视频
Secondary Active Transport
117.3K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
117.3K
Glucose Transporters
22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
142
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
142
Dipeptidyl Peptidase 4 Inhibitors
162
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
162
Glucose Absorption Into the Small Intestine
31.2K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.2K
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
54
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
54


